Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.79 |
| ▸ | MEN1 | O00255 | 5/20 | 0.79 |
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23063977 | 0.95 | KMT2A (0.72) | KMT2AMEN1RAB9ANPC1LMNA | |
| SCHEMBL8661871 | 0.87 | MEN1 (0.82) | KMT2AMEN1RAB9ANPC1LMNA | |
| SCHEMBL9671985 | 0.86 | TSHR (0.77) | KMT2AMEN1RAB9ANPC1GAA | |
| SCHEMBL2351620 | 0.85 | MEN1 (0.79) | KMT2AMEN1RAB9ANPC1LMNA | |
| SCHEMBL13989319 | 0.84 | GAA (0.73) | KMT2AMEN1RAB9ANPC1GAA | |
| SCHEMBL5008292 | 0.84 | MEN1 (0.77) | KMT2AMEN1RAB9ANPC1LMNA | |
| SCHEMBL1245786 | 0.84 | MEN1 (0.77) | KMT2AMEN1RAB9ANPC1LMNA | |
| SCHEMBL21590314 | 0.84 | MEN1 (0.83) | KMT2AMEN1RAB9ANPC1LMNA | |
| SCHEMBL5803982 | 0.84 | MEN1 (0.77) | KMT2AMEN1RAB9ANPC1LMNA | |
| SCHEMBL5803980 | 0.84 | MEN1 (0.77) | KMT2AMEN1RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118930548-A | Menin-MLL protein inhibitor, pharmaceutical composition and application thereof | 赛诺哈勃药业（成都）有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-01 | — | — | US | disclosed |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-01 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-7381517-B2 | Curable composition and image forming material containing the same | FUJIFILM CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-4313874-A | DYEING POLYESTERS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | CD4, CD40LG, CD14 | KMT2A 4046/4885MEN1 4376/4885RAB9A 4442/4885 |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | KMT2A 3492/4885MEN1 3895/4885RAB9A 2332/4885 |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | KMT2A 1619/4885MEN1 855/4885RAB9A 616/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | KMT2A 37/4885MEN1 3832/4885RAB9A 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.